Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by R. Qin
Based on 1 article published since 2009
(Why 1 article?)
||||

Between 2009 and 2019, R. Qin wrote the following article about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Article Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer. 2015

Qin, R / Smyrk, T C / Reed, N R / Schmidt, R L / Schnelldorfer, T / Chari, S T / Petersen, G M / Tang, A H. ·Department of Health Sciences Research, Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN 55905, USA. · Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN 55905, USA. · Department of Surgery, Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN 55905, USA. · 1] Department of Biochemistry and Molecular Biology, Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN 55905, USA [2] Upper Iowa University, Fayette, IA 52142, USA. · 1] Department of Medicine, Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN 55905, USA [2] Department of Oncology, Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN 55905, USA. · 1] Department of Surgery, Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN 55905, USA [2] Department of Biochemistry and Molecular Biology, Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN 55905, USA [3] Department of Microbiology and Molecular Cell Biology, Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA 23507, USA. ·Br J Cancer · Pubmed #25584484.

ABSTRACT: BACKGROUND: The dismal prognosis of patients diagnosed with pancreatic cancer points to our limited arsenal of effective anticancer therapies. Oncogenic K-RAS hyperactivation is virtually universal in pancreatic cancer, that confers drug resistance, drives aggressive tumorigenesis and rapid metastasis. Pancreatic tumours are often marked by hypovascularity, increased hypoxia and ineffective drug delivery. Thus, biomarker discovery and developing innovative means of countervailing oncogenic K-RAS activation are urgently needed. METHODS: Tumour specimens from 147 pancreatic cancer patients were analysed by immunohistochemical (IHC) staining and tissue microarray (TMA). Statistical correlations between selected biomarkers and clinicopathological predictors were examined to predict survival. RESULTS: We find that heightened hypoxia response predicts poor clinical outcome in resectable pancreatic cancer. SIAH is a tumour-specific biomarker. The combination of five biomarkers (EGFR, phospho-ERK, SIAH, Ki67 and HIF-1α) and four clinicopathological predictors (tumour size, pathological grade, margin and lymph node status) predict patient survival post surgery in pancreatic cancer. CONCLUSIONS: Combining five biomarkers in the K-RAS/Ki67/HIF-1α pathways with four clinicopathological predictors may assist to better predict survival in resectable pancreatic cancer.